Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Snyder

Showing results (301-310 of 320) with videos related to

Pageof 32
Sort By:
ACS Medicinal Chemistry Letters|June 6, 2014
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical StilbenesJeffrey L Romine, Denis R St Laurent, John E Leet, et al.
Virology|July 31, 2013
Characterizations of HCV NS5A replication complex inhibitorsDonald R O'Boyle Ii, Jin-Hua Sun, Peter T Nower, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2013
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivativesMakonen Belema, Van N Nguyen, Denis R St Laurent, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2016
Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool boxHong Huang, Andrew P Degnan, Anand Balakrishnan, et al.
Physical Review Letters|August 29, 2014
Reduction of edge-localized mode intensity using high-repetition-rate pellet injection in tokamak H-mode plasmasL R Baylor, N Commaux, T C Jernigan, et al.
Molecular Cancer Therapeutics|June 20, 2015
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor VasculatureAlberto Visintin, Kelly Knowlton, Edyta Tyminski, et al.
Public Health Reports (Washington, D.C. : 1974)|November 24, 2025
Acute Care Use Among People With Sickle Cell Disease, Sickle Cell Data Collection Program, 8 US States, 2018Parker Parks, Joshua I Miller, Shamaree Cromartie Jones, et al.
Nature|April 23, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Richard E Nettles, Makonen Belema, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Pageof 32

Showing results (301-310 of 320) with videos related to

Sort By:
Pageof 32
ACS Medicinal Chemistry Letters|June 6, 2014
Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical StilbenesJeffrey L Romine, Denis R St Laurent, John E Leet, et al.
Virology|July 31, 2013
Characterizations of HCV NS5A replication complex inhibitorsDonald R O'Boyle Ii, Jin-Hua Sun, Peter T Nower, et al.
Bioorganic & Medicinal Chemistry Letters|June 28, 2013
HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivativesMakonen Belema, Van N Nguyen, Denis R St Laurent, et al.
Bioorganic & Medicinal Chemistry Letters|August 7, 2016
Oxazolidinone-based allosteric modulators of mGluR5: Defining molecular switches to create a pharmacological tool boxHong Huang, Andrew P Degnan, Anand Balakrishnan, et al.
Physical Review Letters|August 29, 2014
Reduction of edge-localized mode intensity using high-repetition-rate pellet injection in tokamak H-mode plasmasL R Baylor, N Commaux, T C Jernigan, et al.
Molecular Cancer Therapeutics|June 20, 2015
Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor VasculatureAlberto Visintin, Kelly Knowlton, Edyta Tyminski, et al.
Public Health Reports (Washington, D.C. : 1974)|November 24, 2025
Acute Care Use Among People With Sickle Cell Disease, Sickle Cell Data Collection Program, 8 US States, 2018Parker Parks, Joshua I Miller, Shamaree Cromartie Jones, et al.
Nature|April 23, 2010
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effectMin Gao, Richard E Nettles, Makonen Belema, et al.
Bioorganic & Medicinal Chemistry Letters|September 11, 2012
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamidesDenis R St Laurent, Makonen Belema, Min Gao, et al.
Journal of Medicinal Chemistry|January 21, 2014
Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b repliconsMakonen Belema, Van N Nguyen, Jeffrey L Romine, et al.
Pageof 32